lexion Pharmaceuticals
- Business
AstraZeneca buying drug developer Alexion for $39 billion
“This acquisition allows us to enhance our presence in immunology,” AstraZeneca CEO Pascal Soriot said in a statement. Pharmaceutical company…
Read More »
“This acquisition allows us to enhance our presence in immunology,” AstraZeneca CEO Pascal Soriot said in a statement. Pharmaceutical company…
Read More »